Evidence map›Paper›PMID 36732773›Full record

ArticleHarm reduction journal2023

The effects of COVID-19 on New York State's Drug User Health Hubs and syringe service programs: a qualitative study.

Mercy Ude, Czarina N Behrends, Shea Kelly, Bruce R Schackman, Allan Clear, Rebecca Goldberg, Kitty Gelberg, Shashi N Kapadia

Open access · goldAbstract read
In one paragraph

Article in Harm reduction journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mercy UdeWeill Cornell Medical College, New York, NY, 10065, USA.
Czarina N BehrendsDepartment of Population Health Sciences, Weill Cornell Medical College, New York, NY, 10065, USA.
Shea KellyNew York State Department of Health, New York, NY, 10007, USA.
Bruce R SchackmanDepartment of Population Health Sciences, Weill Cornell Medical College, New York, NY, 10065, USA.
Allan ClearNew York State Department of Health, New York, NY, 10007, USA.
Rebecca GoldbergNew York State Department of Health, New York, NY, 10007, USA.
Kitty GelbergNew York State Department of Health, New York, NY, 10007, USA.
Shashi N KapadiaDepartment of Population Health Sciences, Weill Cornell Medical College, New York, NY, 10065, USA. shk9078@med.cornell.edu.
Cornell University · USNew York State Department of Health · US

Funding

Utilization of health services after engagement with opioid use disorder (OUD) treatment provider by individuals with and without post-traumatic stress disorderP30DA040500 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI Bruce R Schackman · 2015 to 2026
$20.7M
Evaluation of Community-based Drug User Health Hubs to Reduce Opioid Overdoses in NY StateR01CE003022 · CE · CENTER OF ENVIRONMENTAL HEALTH · PI CLEAR, ALLAN · 2018 to 2020
$2.2M
Integrated Care for Hepatitis C: Current Uptake & Impact on Future TreatmentK01DA048172 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI KAPADIA, SHASHI · 2019 to 2023
$948k
NCIPC CDC HHS R01 CE003022NIDA NIH HHS K01 DA048172NIDA NIH HHS P30 DA040500
6 · The paper itself

Abstract

backgroundSyringe service programs (SSPs) deliver critical harm reduction services to people who inject drugs (PWID). Some SSPs in New York State received enhanced funding to provide additional services to combat opioid overdose fatalities. These SSPs, known as Drug User Health Hubs, provide buprenorphine for the treatment of opioid use disorder and other health-related services in addition to their syringe services. While the COVID-19 pandemic posed widespread challenges to the delivery of health services nationwide, the effect of the pandemic on SSPs uniquely impacts PWID. This study examines the impact of COVID-19 on service delivery of Drug User Health Hubs and stand-alone SSPs in New York State.

methodsBetween July 2020 and September 2020, we performed eleven semi-structured virtual interviews with staff from three Health Hub SSPs and three stand-alone SSPs. The interviews explored the effect of the COVID-19 pandemic on SSPs and their clients as well as the changes implemented in response. Interviews were recorded and transcribed. We performed content analysis to identify emerging themes from the data.

resultsDue to the COVID-19 pandemic, some SSPs temporarily shut down while others limited their hours of operation. SSPs modified their service delivery to maintain syringe services and naloxone distribution over other services such as STI and HCV testing. They virtualized components of their services, including telemedicine for the provision of buprenorphine. While SSPs found virtualization to be important for maintaining their services, it negatively impacted the intimate nature of client interactions. Participants also described the impact of the pandemic on the well-being of PWID, including isolation, worsened mental health challenges, and increased drug overdoses.

conclusionsIn response to the COVID-19 pandemic, SSPs demonstrated innovation, adaptability, and togetherness. Despite the challenges posed by the pandemic, SSPs continued to be key players in maintaining access to sterile supplies, buprenorphine, and other services for PWID. In addition to adapting to COVID-19 restrictions, they also responded to the dynamic needs of their clients. Sustainable funding and recognition of the critical role of SSPs in supporting PWID can help to improve outcomes for PWID.

Indexed as

BuprenorphineCOVID-19Drug UsersSubstance Abuse, IntravenousHumansNeedle-Exchange ProgramsNew YorkPandemicsSyringesBuprenorphineCOVID-19Harm reductionPeople who inject drugsSyringe services programTelemedicine

Identifiers

PMID36732773
PMCPMC9893960
OpenAlexW4318981575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.